113 results about "Lung squamous cell carcinoma" patented technology

The invention relates to a the field of biomedicine, and specifically relates to a model for predicting prognosis of lung squamous cell carcinoma with seven genes as biomarkers, and an establishing method thereof. The model for predicting prognosis of lung squamous cell carcinoma includes seven genes related to prognosis of lung squamous cell carcinoma: CSRNP1, CLEC18B, MIR27A, AC130456.4, DEFA6,ARL14EPL and ZFP42, wherein expressions of CSRNP1 and CLEC18B are positively correlated with a survival rate while expressions of MIR27A, AC130456.4, DEFA6, ARL14EPL and ZFP42 are negatively correlated with the survival rate. The model for predicting prognosis of lung squamous cell carcinoma provides a plurality of genes as biomarkers, and improves the prognosis sensitivity and accuracy for predicting lung squamous cell carcinoma, thereby reducing mortality and local recurrence rate in patients with lung squamous cell carcinoma, and improving the prognosis of patients through the risk prediction model.

The present invention is a method distinguishing between head and neck squamous cell carcinoma and lung squamous cell carcinoma. In particular, a 10-gene classifier has been identified which can be used to distinguish between primary squamous cell carcinoma of the lung and metastatic head and neck squamous cell carcinoma. These genes include CXCL13, COL6A2, SFTPB, KRT14, TSPYL5, TMP3, KLK10, MMP1, GAS1, and MYH2. A panel of one or more of these genes, or proteins encoded thereby, can be used for early diagnosis and selection of an appropriate therapeutic treatment.

The present invention relates to markers and diagnostic reagents for the diagnosis or prognosis of lung cancer. The present invention discloses for the first time that DDX56 is significantly increasedin patients with early disease progression (= 12 months) after treatment of two major subtypes of small cell lung cancer (lung squamous cell carcinoma, lung adenocarcinoma), and that the increased expression of DDX56 significantly affects the overall survival of the patients. Therefore, DDX56 can be used as a diagnostic marker for early recurrence of lung squamous cell carcinoma or lung adenocarcinoma.

The invention relates to the field of biotechnologies, and in particular relates to a group of LncRNA biological markers for diagnosing human lung squamous carcinoma, a related kit and applications thereof. The group of LncRNA biological markers for diagnosing the human lung squamous carcinoma, provided by the invention, comprises ENST00000453324, ENST00000441841, uc011cly.2, NR_028500 and NR_046326. The LncRNA biological markers for diagnosing the human lung squamous carcinoma can be used for distinguishing human early lung squamous carcinoma, the AUC value of the LncRNA biological markers for distinguishing the early lung squamous carcinoma and pairing normal lung tissues can reach 0.932, and the sensitivity and the specificity can be 92% and 87% respectively.

The invention provides microRNA (micro ribonucleic acid) for identification of subtypes of a lung cancer. The miroRNA is chosen from the following sequence: a) a sequence shown as SEQ ID No. n (sequence identification number), or b) microRNA complementary to the sequence shown as SEQ ID No. n, wherein the n is 2, 3, 4 or 7. The invention further provides an application of the microRNA and a reagent kit based on the microRNA. The invention further provides a set formed by the microRNA, an application of the set and a reagent kit based on the set. The miroRNA has the advantages that the microRNA can form two combinations, namely SEQ ID No.2 and SEQ ID No.7, as well as SEQ ID No.3 and SEQ ID No.4, which can be used to differentially diagnose the small cell lung cancer, non-small cell lung cancer, adenocarcinoma lung cancer and squamous cell lung cancer respectively; the diagnosis is high in speed, low in cost and accurate and reliable in result; and a significant basis is provided for performing precise targeted therapy on a patient with the lung cancer.

The invention provides a lung cell pathology rapid on-site evaluation system and method and a computer readable storage medium, which are used for rapidly evaluating a cell sample on an operation site. The lung cell pathology rapid on-site evaluation system comprises a microscopic image acquisition device which comprises an objective table used for bearing a lung cell sample and a camera used forshooting the cell sample to obtain a microscopic image of the sample; an image evaluation device with a neural network classification model used for classifying the microscopic images, wherein the obtained classification result is one of lung squamous cell carcinoma, lung adenocarcinoma, small cell lung cancer, unclear non-small cell lung cancer, other malignant lesions, no obvious abnormality, granuloma and inflammation; and an output device connected to the image evaluation device and used for outputting the classification result to a user. According to the invention, the neural network classification model is used for evaluating the microscopic image acquired by the microscopic image acquisition device, and an evaluation result is obtained on an operation site, so that the problems thatthe current cell pathological diagnosis is complex and time-consuming, and the pathological diagnosis result cannot be obtained immediately are solved, and the diagnosis efficiency is effectively improved.

The invention discloses a reagent for auxiliarily diagnosing lung cancer lymph node metastasis, comprising 8 antibodies which are used for detecting 8 protein markers which are MMP1 (matrix metalloproteinase-1), TIMP1 (tissue inhibitor of metalloproteinases metallopeptidase inhibitor 1), IQGAP1 (IQ motif containing GTPase activating protein 1), TPX2 (targeting protein for Xklp2), uPA (Urokinase-type plasminogen activator), Cathepsin-D, Fascin and pIgR/SC (polymeric immunoglobulin receptor/secretory component). By adopting the 8 antibodies and an immunohistochemical staining result, lung cancer lymph node metastasis can be auxiliarily diagnosed, and the reagent is expected to be used for the risk estimation of lung squamous cell cancer lymph node metastasis and the prognostic prediction. The reagent has high creditability, strong practicability and clinical use value based on the clinical routine immunohistochemical staining technology when the reagent is used for auxiliary diagnosis.

The invention relates to a prognosis prediction model for squamous cell carcinoma and application thereof. The prognosis prediction model is composed of biomarkers CFLAR, RGS19, PINK1, CTSD and related solutions. The invention also comprises application of a reagent for detecting the expression quantity of the biomarkers in preparation of a kit for evaluating the anti-tumor immunotherapy reactivity and prognosis survival of squamous cell carcinoma. According to the invention, screening and construction are carried out after whole transcriptome sequencing and machine learning of squamous cell carcinoma samples of large-sample anti-tumor immunotherapy, so that the reactivity of squamous cell carcinoma patients in anti-tumor immunotherapy can be efficiently and accurately predicted, effective guidance is provided for clinicians to make treatment decisions on squamous cell carcinoma patients, and the occurrence of invalid treatment is reduced, thereby reducing the treatment cost and discomfort experience of patients.

The invention discloses a lung glandular squamous cell carcinoma diagnosis device based on PET/CT image subarea imaging omics characteristics, and belongs to the field of medical images. The diagnosisdevice comprises: a voxel three-dimensional feature extraction module, which is used for extracting a CT local main gradient angle feature value of each voxel of a lung tumor in a neighborhood in a PET/CT image, a CT value of the voxel and a PET value, and forming a three-dimensional feature vector of the voxel; a feature clustering module used for clustering the obtained three-dimensional feature vector of each voxel to obtain a tumor sub-region partition; a radios image omics feature extraction module used for extracting radios image omics features of each tumor sub-region in a partitioningmanner; and a classification module used for distinguishing whether the tumor is lung squamous cell carcinoma or lung adenocarcinoma according to the extracted radiomics characteristics of the radiomics. According to the diagnosis device, the heterogeneity in the tumor is better considered, and the accuracy of tumor diagnosis is effectively improved by extracting more effective imaging omics characteristics.

The invention discloses a system for predicting the prognosis of a patient with lung squamous cell carcinoma. The system includes a subsystem for detecting the expression quantity of such five proteins as EGFR, p38alpha, AKT1, SOX2 and E-cadherin and a protein expression quantity data processing system. The subsystem for detecting the expression quantity of the five proteins is allowed to measure the expression quantity of the proteins through an immunohistochemistry staining method; the protein expression quantity data processing system is allowed to convert the expression quantity of the five proteins from the squamous cell carcinoma tissues separated from the patient with the lung squamous cell carcinoma to a prognostic score; based on the prognostic score, the prognosis of a patient with the lung squamous cell carcinoma is predicted.

The invention discloses a non-small cell lung cancer subtype classification system based on multi-view deep learning, which realizes classification of lung adenocarcinoma and lung squamous carcinoma based on a CT image, generates and displays image data of an examined part based on volume data generated by performing lung CT on an examined body, and obtains non-small cell lung cancer subtype classification result of the examined body. The non-small cell lung cancer pathological subtype classification system comprises an information acquisition module, a network module and a training module. According to the system, automatic lung field segmentation can be realized, interlayer information and three-dimensional information carried by a CT image are fully utilized by a multi-view model, an obtained classification model can be used as a tool for assisting a doctor through automatic feature extraction and classification training, and the system has the characteristics of high automation and high practicability.

The invention relates to the technical field of bio-medicine, in particular to application of PINK1 serving as a diagnostic marker in construction of a lung squamous cell carcinoma prognosis prediction model. The biomarker PINK1 and other clinical indexes are used in a combined mode, and lung squamous cell carcinoma prognosis detection can be assisted. According to the invention, screening and construction are carried out after full transcriptome sequencing and machine learning of a lung squamous cell carcinoma specimen based on large-sample anti-tumor immuno-therapy, so that the prognosis condition of a lung squamous cell carcinoma patient can be efficiently and accurately predicted; and meanwhile, according to the correlation between the risk and different immune cell infiltration levels, immune-related pathways, key immune checkpoint inhibitor expression levels and the like, comprehensive evaluation of the tumor immune micro-environment is achieved, effective guidance is provided for clinicians to make a treatment decision on lung squamous cell carcinoma patients, invalid treatment is reduced, and therefore, the treatment cost and discomfort experience of the patients are reduced.

The invention discloses a circRNA composition marker for diagnosing and identifying non-small cell lung cancer (NSCLC) subtypes and application of the circRNA composition marker, including applicationof hsa_circ_0069841, hsa_circ_001357 and a combination of hsa_circ_001357 and hsa_circ_0069841 in identifying the NSCLC subtypes, and further provides a kit and gene chip prepared from a reagent fordetecting the hsa_circ_0069841, the hsa_circ_001357 and the combination of the hsa_circ_001357 and the hsa_circ_0069841. It is found that the hsa_circ_0069841 and the hsa_circ_001357 can have remarkable specificity and sensitivity to identification of lung adenocarcinoma and lung squamous cell carcinoma in the NSCLC independently or in a combined mode, the diagnosis speed is high, the cost is low,the result is accurate and reliable, rapid and accurate identification of lung cancer subtypes is facilitated through the prepared kit and gene chip, and a reliable basis is provided for targeted therapy of NSCLC patients.

Methods and compositions are provided for determining a subtype of lung squamous cell carcinoma (SQ) of an individual by detecting the expression level of at least one classifier biomarker selected from a group of gene signatures for lung squamous cell carcinoma. Also provided herein are methods and compositions for determining the response of an individual with a squamous cell carcinoma subtype to a therapy such as immunotherapy.

The invention relates to the field of nano medicine, and especially relates to a fluorescence imaging probe, a preparation method and applications thereof. The nano fluorescence imaging probe comprises a material having a metal-organic skeleton structure and heavy metal ions. The probe can enter lung cancer cells through endocytosis. The nano fluorescence imaging probe can stimulate different lung cancer cells to generate different contents of metallothionein, then the probe can combine with metallothionein, then the probe and metallothionein are discharged from the cells, and the amount of residual nano fluorescence imaging probe in cells will determine the intensity of cell fluorescence images, so according to the difference of intensity of cell fluorescence images, the lung squamous cell carcinoma and lung adenocarcinoma can be precisely differentiated.

The present invention provides a method by which lung squamous cell carcinoma can be detected in a simple and prompt manner with high detection performance; and the like. The method according to the present invention detects lung squamous cell carcinoma by an assessment including the steps of: (1) performing measurement of the desmoglein 3 content in a blood sample collected from a subject; and (2) comparing the desmoglein 3 content determined by the measurement with the desmoglein 3 content in a blood sample collected from a healthy individual so as to estimate the presence of lung squamous cell carcinoma in the subject when the desmoglein 3 content is higher in the blood sample collected from the subject.

The invention relates to a rare earth probe capable of carrying out target recognition of lung squamous cell carcinoma, and a preparation method and application thereof. The rare earth probe is a core-shell structure formed by coating a lanthanide fluoride oxide containing an up-conversion luminous element with a lanthanide fluoride oxide containing a near-infrared second-region fluorescent imaging element, and a structure general formula is: ReOF:Ln@ReOF:Ln', wherein Re, Ln, and Ln' are all lanthanide elements. The rare earth probe has good up-conversion luminescence performance and near-infrared second-region fluorescence performance at the same time, is relatively strong in fluorescence intensity, has adjustable up-conversion fluorescence color, can realize dual-mode imaging effects, isa nano-probe with excellent fluorescence performance, and has good luminous effects.

The invention provides a noninvasive test kit of a susceptibility gene of lung squamous carcinoma. The kit comprises a specific primer of two single nucleotide polymorphism locus gene types for detecting whether Lys75Gln and GSTT1 genes on an XPD (Xeroderma Pigmentosum group D) gene are lacked or not (Present/Null), a DNA (Deoxyribonucleic Acid) sequencing primer, a PCR reaction assembly, a PCR product purifying assembly, a DNA sequencing reaction assembly and the like. The kit is used for estimating a risk grade for a subject suffering the lung squamous carcinoma through detecting the gene types of the two single nucleotide polymorphism loca which are relative to the lung squamous carcinoma; and the subject is guided to prevent the happening of the lung squamous carcinoma in a targeted manner from a gene level according to a gene detection result of each subject, so as to reduce the morbidity of the subject. A sampling method of the invention is as follows: an oral mucosa cell is sampled, the purposes of being painless and noninvasive and avoiding crossed infection can be realized. A sequencing detection result is accurate and reliable, a special imported instrument with expensive cost does not need to be purchased, and the method is easy to popularize and spread.

The present invention provides for new markers for the detection of HPV-induced or lung squamous cell carcinoma and/or adenocarcinoma and high-grade precursor lesions thereof, comprising the genes of the present invention. Detection can take place by detection over expression or down regulation of said genes either by nucleic acid assay or by assays for the proteins produced by said genes.

The invention provides a reagent, kit and method for detecting mutations of genes related to a lung squamous cell carcinoma anti-oxidative stress driving pathway. Genes related to the anti-oxidative stress pathway are screened by applying RNA sequencing and Lasso algorithm characteristics, a model is constructed by constructing a score RiskScore and applying dichotomy logistic regression, the optimal cut-off value of the score RiskScore in the lung squamous cell carcinoma is obtained through an ROC curve, and the reagent, the kit and the method can be used for predicting the mutation of the genes (KEAP1, NFE2L2 and CUL3) related to the anti-oxidative stress pathway in the lung squamous cell carcinoma. The mutation of the genes related to a specific driving pathway of the lung squamous cell carcinoma is predicted by utilizing the expression quantity obtained by combining the genes, and TCGA database verification shows that the method has the advantages of high sensitivity and good specificity, can effectively guide individualized treatment of patients with the lung squamous cell carcinoma, adds more important hopes for precise treatment and individualized treatment, and improves the clinical benefit.